We have begun to develop a research agenda for Global Catastrophic Biological Risks. Our work has involved horizon-scanning for emerging issues in biotechnology, analysing gene drives, and debating gain-of-function research. On biosafety, we are developing strategies for promoting responsible research and innovation in collaboration with academics, biotech companies, and bio-hacker communities. On biosecurity, we have developed a collaborative strategy of next steps for the Biological Weapons Convention.
A natural pandemic could kill hundreds of millions of people, an engineered pandemic could kill many more, and threaten civilizational collapse.
The last great influenza pandemic killed between 2.5%-5% of the world population in 1918, far more than World War One. As recent scares over bird flu and swine flu show, this risk has not gone away. Though our scientific knowledge has improved, we are more densely populated, interconnected and entangled with zoonotic reservoirs than before. We need better surveillance, better (inter)national health systems, and better development and stockpiles of vaccines and medical countermeasures.
Estimated percentage of world population killed by the Black Death
However, there is a trade-off in natural pandemics between transmissibility and lethality – if a pathogen kills its host too quickly, the host can’t infect many other people. But due to biotechnological advances, it may soon be possible to engineer pathogens to be more infectious, more fatal, and to have a delayed onset – and so be far more dangerous.
Error or terror: Bad bugs or bad people
New breakthroughs like the targeted genome editing tool CRISPR-Cas9 are increasing our capabilities; and the cost of DNA sequencing/synthesis and the hurdle of expertise are rapidly decreasing. This growing biotechnological knowledge and capability will have many benefits – new and better drugs, improvements to agricultural productivity and environmental protection. But it is a dual-use technology, and so can also be misused in ways that cause harm.
An engineered pandemic could escape from a lab, or it could be deliberately used as a weapon. During the 20th century several countries had state-run bioweapons programmes, and we know of several non-state groups that have attempted to acquire bioweapons.
Almost singlehandedly, one postdoc was recently able to recreate horsepox (similar to smallpox, which killed 300m in the 20th Century) from scratch in only six months. Capabilities that were once only in the hands of governments will soon be within reach of non-state actors.
A novel pathogen, designed to be deadlier than anything in nature, could severely affect the entire world. As Lord Rees has said “The global village will have its village idiots, and they'll have global range”.
Public Mental Health and COVID-19: a compassion based approach to recovery and resilience
Point of View: A transatlantic perspective on 20 emerging issues in biological engineering
Peer-reviewed paper by Bonnie Wintle, Catherine Rhodes, Seán Ó hÉigeartaigh, Christian R. Boehm, William Sutherland, Robert Doubleday, Jennifer C Molloy, Piers Millett, Laura Adam, Rainer Breitling, Rob Carlson, Rocco Casagrande, Malcolm Dando, Eric Drexler, Brett Edwards, Tol Ellis, Nicholas G Evans, Richard Hammond, Jim Haseloff, Linda Kahl, Todd Kuiken, Benjamin R Lichman, Colette A Matthewman, Johnathan A Napier, Nicola J Patron, Edward Perello, Philip Shapira, Joyce Tait, Eriko Takano
Risks and Benefits of Gain-of-Function Experiments in Potentially Pandemic Pathogens
Video by Derek Smith, Marc Lipsitch
Embrace experimentation in biosecurity governance
Peer-reviewed paper by Sam Weiss Evans, Jacob Beal, Kavita Berger, Diederik A. Bleijs, Alessia Cagnetti, Francesca Ceroni, Gerald L. Epstein, Natàlia Garcia-Reyero, David R. Gillum, Graeme Harkess, Nathan J. Hillson, Petra A. M. Hogervorst, Jacob L. Jordan, Geneviève Lacroix, Rebecca Moritz, Seán Ó hÉigeartaigh, Megan J. Palmer, Mark W. J. van Passel
Informing management of lockdowns and a phased return to normality: a Solution Scan of non-pharmaceutical options to reduce SARS-CoV-2 transmission
Report by William Sutherland, David C. Aldridge, Philip Martin, Catherine Rhodes, Gorm Shackelford, S. J. Beard, Andrew J. Bladon, Cameron Brick, Mark Burgman, Alec P. Christie, Lynn V. Dicks, Andrew P. Dobson, Harriet Downey, Fangyuan Hua, Amelia S.C. Hood, Alice C. Hughes, Rebecca M. Jarvis, Douglas MacFarlane, Anne-Christine Mupepele, William H. Morgan, Seán Ó hÉigeartaigh, Stefan J. Marciniak, Cassidy Nelson, Clarissa Rios Rojas, Katherine A. Sainsbury, Rebecca K. Smith, Lalitha Sundaram, Hannah Tankard, Nigel G. Taylor, Ann Thornton, John Watkins, Thomas B. White, Kate Willott, Silviu O. Petrovan, Haydn Belfield
Point of View: Bioengineering horizon scan 2020
Peer-reviewed paper by Luke Kemp, Laura Adam, Christian R. Boehm, Rainer Breitling, Rocco Casagrande, Malcolm Dando, Appolinaire Djikeng, Nicholas Evans, Richard Hammond, Kelly Hills, Lauren Holt, Todd Kuiken, Alemka Markotić, Piers Millett, Johnathan A Napier, Cassidy Nelson, Seán Ó hÉigeartaigh, Anne Osbourn, Megan Palmer, Nicola J Patron, Edward Perello, Wibool Piyawattanametha, Vanessa Restrepo-Schild, Clarissa Rios Rojas, Catherine Rhodes, Anna Roessing, Deborah Scott, Philip Shapira, Christopher Simuntala, Robert DJ Smith, Lalitha Sundaram, Eriko Takano, Gwyn Uttmark, Bonnie Wintle, Nadia B Zahra, William Sutherland